Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …

Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the
leading causes of chronic liver disease worldwide. NAFLD and ALD share …

Fatty liver disease (FLD) caused by metabolic dysfunction is the leading cause of liver
disease and the prevalence is rising, especially in women. Although during reproductive …

Non-alcoholic fatty liver disease (NAFLD) with its more progressive form non-alcoholic
steatohepatitis (NASH) has become the most common chronic liver disease, thereby …

Liver fibrosis, as an excess deposition of extracellular matrix (ECM) components, results
from chronic liver injury as well as persistent activation of inflammatory response and of …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an unabated risk factor
for end-stage liver diseases with no available therapies. Dysregulated immune responses …

Conclusions Metabolomic signatures identify three NAFLD subgroups, independent of
histological disease severity. These signatures align with known CVD and genetic risk …

With the aging of global population, the incidence of nonalcoholic fatty liver disease
(NAFLD) has surged in recent decades. NAFLD is a multifactorial disease that follows a …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a global
prevalence estimated at approximately 25%. NAFLD is also the leading cause of liver …

Abstract Background and Aims We previously identified subsets of patients with NAFLD with
different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular …